A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Chief Scientific Officer Dr. Daniel Skovronsky talked with the IBJ about his hopes for the Lilly Medicine Foundry, which the ...

President Donald Trump signed an executive order aimed at reducing approval time for pharmaceutical plants to encourage ...

A new executive order from President Donald Trump aims to cut down the 5-to-10-year timeline to build new facilities while ...

(Reuters) -U.S. President Donald Trump will sign an executive order on Monday to streamline regulations surrounding ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...

The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its [tariff rollout]( ...

Ricks said reshoring manufacturing capacity for older essential medicines is "a valid thing," adding that Eli Lilly is "happy ...

As broader approval for GLP-1 weight loss drugs spurs higher demand, it’s also causing employer drug spending to spike.

The regulator has given larger so-called outsourcing facilities, which make compounded drugs in bulk and are regulated by the agency, until May 22. Smaller compounding pharmacies, which make drugs to ...